Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 129

1.

Protective efficacy of Modified Vaccinia virus Ankara in preclinical studies.

Volz A, Sutter G.

Vaccine. 2013 Sep 6;31(39):4235-40. doi: 10.1016/j.vaccine.2013.03.016. Epub 2013 Mar 21. Review.

PMID:
23523402
2.

Clinical development of Modified Vaccinia virus Ankara vaccines.

Gilbert SC.

Vaccine. 2013 Sep 6;31(39):4241-6. doi: 10.1016/j.vaccine.2013.03.020. Epub 2013 Mar 21. Review.

PMID:
23523410
3.

Vaccinia vectors as candidate vaccines: the development of modified vaccinia virus Ankara for antigen delivery.

Sutter G, Staib C.

Curr Drug Targets Infect Disord. 2003 Sep;3(3):263-71. Review.

PMID:
14529359
4.

Modified Vaccinia Virus Ankara: History, Value in Basic Research, and Current Perspectives for Vaccine Development.

Volz A, Sutter G.

Adv Virus Res. 2017;97:187-243. doi: 10.1016/bs.aivir.2016.07.001. Epub 2016 Aug 1. Review.

PMID:
28057259
5.

Recombinant MVA vaccines: dispelling the myths.

Cottingham MG, Carroll MW.

Vaccine. 2013 Sep 6;31(39):4247-51. doi: 10.1016/j.vaccine.2013.03.021. Epub 2013 Mar 21. Review.

PMID:
23523407
6.

Modified Vaccinia virus Ankara: innate immune activation and induction of cellular signalling.

Price PJ, Torres-Domínguez LE, Brandmüller C, Sutter G, Lehmann MH.

Vaccine. 2013 Sep 6;31(39):4231-4. doi: 10.1016/j.vaccine.2013.03.017. Epub 2013 Mar 21. Review.

PMID:
23523404
7.

Enhanced immunogenicity and protective effect conferred by vaccination with combinations of modified vaccinia virus Ankara and licensed smallpox vaccine Dryvax in a mouse model.

Meseda CA, Garcia AD, Kumar A, Mayer AE, Manischewitz J, King LR, Golding H, Merchlinsky M, Weir JP.

Virology. 2005 Sep 1;339(2):164-75.

8.

Expanding the repertoire of Modified Vaccinia Ankara-based vaccine vectors via genetic complementation strategies.

Garber DA, O'Mara LA, Zhao J, Gangadhara S, An I, Feinberg MB.

PLoS One. 2009;4(5):e5445. doi: 10.1371/journal.pone.0005445. Epub 2009 May 6.

9.
10.

Modified vaccinia Ankara: potential as an alternative smallpox vaccine.

McCurdy LH, Larkin BD, Martin JE, Graham BS.

Clin Infect Dis. 2004 Jun 15;38(12):1749-53. Epub 2004 May 19.

PMID:
15227622
11.

Candidate influenza vaccines based on recombinant modified vaccinia virus Ankara.

Rimmelzwaan GF, Sutter G.

Expert Rev Vaccines. 2009 Apr;8(4):447-54. doi: 10.1586/erv.09.4. Review.

PMID:
19348560
12.

Immunogenicity and safety of defective vaccinia virus lister: comparison with modified vaccinia virus Ankara.

Ober BT, Brühl P, Schmidt M, Wieser V, Gritschenberger W, Coulibaly S, Savidis-Dacho H, Gerencer M, Falkner FG.

J Virol. 2002 Aug;76(15):7713-23.

13.

The nonreplicating smallpox candidate vaccines defective vaccinia Lister (dVV-L) and modified vaccinia Ankara (MVA) elicit robust long-term protection.

Coulibaly S, Brühl P, Mayrhofer J, Schmid K, Gerencer M, Falkner FG.

Virology. 2005 Oct 10;341(1):91-101.

14.

Vectors based on modified vaccinia Ankara expressing influenza H5N1 hemagglutinin induce substantial cross-clade protective immunity.

Hessel A, Schwendinger M, Holzer GW, Orlinger KK, Coulibaly S, Savidis-Dacho H, Zips ML, Crowe BA, Kreil TR, Ehrlich HJ, Barrett PN, Falkner FG.

PLoS One. 2011 Jan 24;6(1):e16247. doi: 10.1371/journal.pone.0016247.

15.
16.

[Modified vaccinia virus ankara (MVA)--development as recombinant vaccine and prospects for use in veterinary medicine].

Volz A, Fux R, Langenmayer MC, Sutter G.

Berl Munch Tierarztl Wochenschr. 2015 Nov-Dec;128(11-12):464-72. Review. German.

PMID:
26697713
17.

Biosafety aspects of modified vaccinia virus Ankara (MVA)-based vectors used for gene therapy or vaccination.

Verheust C, Goossens M, Pauwels K, Breyer D.

Vaccine. 2012 Mar 30;30(16):2623-32. doi: 10.1016/j.vaccine.2012.02.016. Epub 2012 Feb 17. Review.

18.

Modified vaccinia virus ankara (MVA) as production platform for vaccines against influenza and other viral respiratory diseases.

Altenburg AF, Kreijtz JH, de Vries RD, Song F, Fux R, Rimmelzwaan GF, Sutter G, Volz A.

Viruses. 2014 Jul 17;6(7):2735-61. doi: 10.3390/v6072735. Review.

19.

Postexposure immunization with modified vaccinia virus Ankara or conventional Lister vaccine provides solid protection in a murine model of human smallpox.

Paran N, Suezer Y, Lustig S, Israely T, Schwantes A, Melamed S, Katz L, Preuss T, Hanschmann KM, Kalinke U, Erez N, Levin R, Velan B, Löwer J, Shafferman A, Sutter G.

J Infect Dis. 2009 Jan 1;199(1):39-48. doi: 10.1086/595565.

PMID:
19012492
20.

Vaccination with recombinant modified vaccinia virus Ankara prevents the onset of intestinal allergy in mice.

Bohnen C, Wangorsch A, Schülke S, Nakajima-Adachi H, Hachimura S, Burggraf M, Süzer Y, Schwantes A, Sutter G, Waibler Z, Reese G, Toda M, Scheurer S, Vieths S.

Allergy. 2013 Aug;68(8):1021-8. doi: 10.1111/all.12192. Epub 2013 Jul 30.

Supplemental Content

Support Center